Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Clinical trial NCT05980949 · RECRUITING
Trial details
- NCT number
- NCT05980949
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-11
- Primary completion
- 2027-09-07
- Enrollment
- 1000
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.